WASHINGTON — Democrats’ drug pricing law will still penalize drugmakers if they hike prices on medicines for patients who have private insurance, a top Medicare official said Thursday.
The penalties may factor into drugmakers’ decisions about how to price their medicines as the new law begins to take effect. Some experts and employers have been concerned that the drug pricing policy reforms that will save money in Medicare could incentivize drugmakers to try to charge more to patients with other forms of insurance coverage.
“One thing that I think is important to know is the inflation rebate is determined on the overall price. So it’s including commercial [prices] in there,” Center for Medicare Director Meena Seshamani told reporters Thursday.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
